Cargando…

Polymorphisms of the BRAF gene predispose males to malignant melanoma

The incidence of malignant melanoma has rapidly increased in recent years. Evidence points to the role of inheritance in melanoma development, but specific genetic risk factors are not well understood. Recent reports indicate a high prevalence of somatic mutations of the BRAF gene in melanomas and m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Peter, Sergi, Consolato, Garbe, Claus
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Short Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC317361/ https://www.ncbi.nlm.nih.gov/pubmed/14617374 http://dx.doi.org/10.1186/1477-3163-2-7

Ejemplares similares

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

BRCA1/2 mutation screening and LOH analysis of lung adenocarcinoma tissue in a multiple-cancer patient with a strong family history of breast cancer
por: Boettger, Melanie Barbara, et al.
Publicado: (2003)

Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition
por: Schmitt, Marisa, et al.
Publicado: (2021)

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models
por: Eigentler, Thomas, et al.
Publicado: (2016)

BRAF Mutation Heterogeneity in Melanoma Lesions
por: SAKAIZAWA, Kaori, et al.
Publicado: (2020)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
por: GLUTSCH, Valerie, et al.
Publicado: (2020)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene
por: Hall, Arnaldur, et al.
Publicado: (2013)

Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen(®) FFPE BRAF qPCR assay
por: Sørensen, Anna Lahn, et al.
Publicado: (2023)

Peptidylarginine Deiminase 2 Gene Polymorphisms in Subjects with Periodontitis Predispose to Rheumatoid Arthritis
por: Massarenti, Laura, et al.
Publicado: (2022)

BRAF Gene and Melanoma: Back to the Future
por: Ottaviano, Margaret, et al.
Publicado: (2021)

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
por: Meckbach, Diana, et al.
Publicado: (2014)

Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
por: Shi, Jianxin, et al.
Publicado: (2014)

Imaging characteristics of cardiac metastases in patients with malignant melanoma
por: Zitzelsberger, Tanja, et al.
Publicado: (2017)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization
por: Hipfel, R, et al.
Publicado: (2000)

BRAF‐mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis
por: Abbati, Francesca, et al.
Publicado: (2021)

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
por: Meckbach, Diana, et al.
Publicado: (2014)

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study
por: Forschner, Andrea, et al.
Publicado: (2020)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
por: Meraz-Torres, Francisco, et al.
Publicado: (2020)

A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition
por: Klein, R Matthew, et al.
Publicado: (2011)

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
por: Carlino, Matteo S, et al.
Publicado: (2016)

Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma
por: Gaiser, Maria Rita, et al.
Publicado: (2017)

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
por: Edmunds, S C, et al.
Publicado: (2003)

Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer
por: Puig-Butille, Joan Anton, et al.
Publicado: (2013)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
por: Ades, Felipe, et al.
Publicado: (2012)

Oral malignant melanoma: A report of two cases with BRAF molecular analysis
por: SOMA, PIER FRANCESCO, et al.
Publicado: (2014)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
por: Liu, Szu-Mam, et al.
Publicado: (2014)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
por: Hardeman, Keisha N., et al.
Publicado: (2017)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
por: Kartolo, Adi, et al.
Publicado: (2022)

A polymorphism in the CYP17 gene is associated with male breast cancer
por: Young, I E, et al.
Publicado: (1999)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma
por: Smalley, Inna, et al.
Publicado: (2019)

Malignant gastrointestinal neuroectodermal tumor with BRAF mutation and a history of malignant melanoma: A case report
por: Yagi, Toshinari, et al.
Publicado: (2021)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a8d3jcgotfgpm1ocir6433hure